Evidence map›Paper›PMID 27783237›Full record

Observational studyClinical rheumatology2017

Biologic therapies and infections in the daily practice of three Italian rheumatologic units: a prospective, observational study.

Paola Cipriani, Onorina Berardicurti, Francesco Masedu, Francesca D'Onofrio, Luca Navarini, Piero Ruscitti, Nicola Maruotti, Domenico Paolo Emanuele Margiotta, Vasiliki Liakouli, Paola Di Benedetto and 5 more

Abstract readMulticenter StudyObservational Study
PubMed Publisher
In one paragraph

Observational study in Clinical rheumatology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.0field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Observational
  10. Observational
  11. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 1 country.

Paola CiprianiRheumatology Division, Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, Delta 6 Building, PO Box 67100, L'Aquila, Italy. paola.cipriani@cc.univaq.it.
Onorina BerardicurtiRheumatology Division, Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, Delta 6 Building, PO Box 67100, L'Aquila, Italy.
Francesco MaseduDivision of Medical Statistic Unit, Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.
Francesca D'OnofrioRheumatologic Clinic, University of Foggia, Foggia, Italy.
Luca NavariniUnit of Allergology, Immunology, Rheumatology, Campus Bio-Medico University, Rome, Italy.
Piero RuscittiRheumatology Division, Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, Delta 6 Building, PO Box 67100, L'Aquila, Italy.
Nicola MaruottiRheumatologic Clinic, University of Foggia, Foggia, Italy.
Domenico Paolo Emanuele MargiottaUnit of Allergology, Immunology, Rheumatology, Campus Bio-Medico University, Rome, Italy.
Vasiliki LiakouliRheumatology Division, Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, Delta 6 Building, PO Box 67100, L'Aquila, Italy.
Paola Di BenedettoRheumatology Division, Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, Delta 6 Building, PO Box 67100, L'Aquila, Italy.
Francesco CarubbiRheumatology Division, Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, Delta 6 Building, PO Box 67100, L'Aquila, Italy.
Marco ValentiDivision of Medical Statistic Unit, Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.
Francesco Paolo CantatoreRheumatologic Clinic, University of Foggia, Foggia, Italy.
Antonella AfeltraUnit of Allergology, Immunology, Rheumatology, Campus Bio-Medico University, Rome, Italy.
Roberto GiacomelliRheumatology Division, Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, Delta 6 Building, PO Box 67100, L'Aquila, Italy.
University of L'Aquila · ITUniversità Campus Bio-Medico · ITUniversity of Foggia · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Since the introduction of biologics, many concerns about the increased risk of infections have been reported and, to date, the real impact of infections on the daily practice in the rheumatologic centers is still largely unknown. In this work, we evaluated the infection rates associated with the use of biologics in a large cohort of patients. A prospective study, between January 2010 and December 2013, enrolling 731 rheumatic patients, was performed. Demographic and disease characteristics, therapies, comorbidities, and infectious events were recorded and statistically analyzed by multivariate analysis. Two-hundred thirty-five infectious episodes were observed in 28.4 % of patients. About total infections, bacteria were identified in 70.6 % of total cases and viruses in 18.3 %. The most common site of not-serious infection was the urinary tract. Duration of disease, longer follow-up, concomitant steroid therapy, and comorbidities were significantly associated with not-serious infection. In our cohort, 17 episodes fulfilled the criteria of serious infection and occurred in 17 different patients (2.3 %), the majority involving the lower respiratory tract. Serious infections were associated with the beginning of biologics in older age. Our prospective, observational study showed that, in daily practice, a lesser rate of serious as well as not-serious infections may be observed in rheumatic patients treated with biologics than those reported in previous papers. The most common sites of not-serious infections are both the urinary and the respiratory tracts, and for serious infections, the respiratory tract. When pathogens were isolated, we did not find any multidrug-resistant organism.

Indexed as

AdultAntirheumatic AgentsArthritis, RheumatoidBiological ProductsFemaleFollow-Up StudiesHumansInfectionsItalyMaleMiddle AgedMultivariate AnalysisProspective StudiesRheumatologyRisk FactorsSpondylarthropathiesAntirheumatic AgentsBiological ProductsTNF protein, humanTumor Necrosis Factor-alphaBiological therapiesInfection and arthritisRheumatoid arthritisSerious infectionSpondyloarthropathiesTNF inhibitor

Identifiers

PMID27783237
OpenAlexW2536137744

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.